Login / Signup

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing.

Qianming BaiHong LvLonglong BaoYu YangXin ZhangHeng ChangTian XueMin RenXiaoli ZhuXiaoyan ZhouWentao Yang
Published in: Breast cancer (Dove Medical Press) (2023)
Group A breast cancer, which has always been unquestionably diagnosed as HER2 amplification, was more likely to be HER2 negative and derived less benefit from anti-HER2 neoadjuvant chemotherapy. Group A breast cancer should be distinguished from classical HER2-positive breast cancers when assessing HER2 FISH, and a larger cohort of Group A patients should be included in further studies.
Keyphrases